IP Library Granted Patent US 7,232,803
Granted Patent B2
US 7,232,803 · App. 10/221,040 · Granted Jun 19, 2007

Antimicrobial compounds and formulations

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,232,803
App. No.
10/221,040
Granted
Jun 19, 2007
Kind
B2
Abstract

The invention relates to the use of a molecule comprising a backbone of 2 to 35 non-hydrogen atoms in length, having covalently attached thereto at least two bulky and lipophilic groups and having at least one more cationic than anionic moiety, in the manufacture of a medicament for destabilizing microbial cell membranes and the use as a membrane acting antimicrobial agent of a molecule comprising a backbone of 2 to 35 non-hydrogen atoms in length, having covalently attached thereto a super bulky and lipophilic group comprising at least 9 non-hydrogen atoms and having at least two more cationic than anionic moieties and to methods of treatment involving such molecules, in particular peptides including peptide derivatives, and peptidomimetics.

Claims (9)

1. A method of destabilizing microbial cell membranes in a patient suffering from or at risk of being affected by a microbial infection which comprises administering to said patient a molecule of 2 to 4 amino acids or equivalent subunits in length, and incorporating a bulky and lipophilic group comprising at least 11 non-hydrogen atoms and containing no more than 2 polar functional groups, wherein said bulky and lipophilic group incorporates one or more closed rings of 5 or more non-hydrogen atoms, said molecule further having at least two more cationic than anionic moieties.

2. A method as claimed in claim 1 , wherein said bulky and lipophilic group comprises at least 13 non-hydrogen atoms.

3. A method as claimed in claim 1 , wherein said super bulky group incorporates 2 closed rings of 5 or more non-hydrogen atoms.

4. A method as claimed in claim 1 wherein said molecule is a peptide, peptide derivative or peptidomimetic.

5. A method as claimed in claim 4 , wherein said molecule comprises a modified C terminus which does not carry a negative charge.

6. A method as claimed in claim 5 , wherein said C terminus is amidated or esterified.

7. A method as claimed in claim 5 or 6 , wherein said modified C terminus comprises a bulky and lipophilic group.

8. A method as claimed in claim 4 wherein said peptide, peptide derivative or peptidomimetic comprises one or more amino acid or equivalent R subunits which comprises a bulky and lipophilic group.

9. A method as claimed in claim 8 , wherein one or more of said amino acid or subunits comprises a cationic moiety.

Assignments (3)
CORRECTIVE ASSIGNMENT TO CORRECT THE ASSIGNEE'S NAME PREVIOUSLY RECORDED AT REEL 018673 FRAME 0955. ASSIGNOR CONFIRMS THE ASSIGNMENT Recorded Mar 2, 2007
From: ALPHARMA AS
To: LYTIX BIOPHARMA AS
Reel/Frame 019048/0060 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 15, 2006
From: ALPHARMA AS
To: LYTIX BIOPHARMA
Reel/Frame 018673/0955 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 27, 2003
From: SVENDSEN, JOHN SIGURD; HAUG, BENGT ERIK; MARKO, ISTVAN; REKDAL, OYSTEIN; SKAR, MERETE LINCHAUSEN; STENSEN, WENCHE; STROM, MORTEN BOHMER
To: ALPHARMA AS
Reel/Frame 013796/0330 →